Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists
AbstractMulti-target-directed ligands (MTDLs) offer new hope for the treatment of multifactorial complex diseases such as Alzheimer’s Disease (AD). Herein, we present compounds aimed at targeting the NMDA and the P2X7 receptors, which embody a different approach to AD therapy. On one hand, we are seeking to delay neurodegeneration targeting the glutamatergic NMDA receptors; on the other hand, we also aim to reduce neuroinflammation, targeting P2X7 receptors. Although the NMDA receptor is a widely recognized therapeutic target in treating AD, the P2X7 receptor remains largely unexplored for this purpose; therefore, the dual inhibitor presented herein—which is open to further optimization—represents the first member of a new class of MTDLs. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 115 KB)
Share & Cite This Article
Karoutzou, O.; Kwak, S.-H.; Lee, S.-D.; Martínez-Falguera, D.; Sureda, F.X.; Vázquez, S.; Kim, Y.-C.; Barniol-Xicota, M. Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists. Molecules 2018, 23, 230.
Karoutzou O, Kwak S-H, Lee S-D, Martínez-Falguera D, Sureda FX, Vázquez S, Kim Y-C, Barniol-Xicota M. Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists. Molecules. 2018; 23(1):230.Chicago/Turabian Style
Karoutzou, Olga; Kwak, Seung-Hwa; Lee, So-Deok; Martínez-Falguera, Daina; Sureda, Francesc X.; Vázquez, Santiago; Kim, Yong-Chul; Barniol-Xicota, Marta. 2018. "Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists." Molecules 23, no. 1: 230.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.